Press Releases
-
Advanced BioDesign accelerates ODYSSEY clinical trial with a new design following ABD-3001’s highly promising initial results in Acute Myeloid Leukemia
• Initial clinical data for ABD-3001 in AML have led French health authorities to approve a compassionate use program for the treatment. • Thanks to…
-
Advanced BioDesign: A new study published in the Journal of Cellular Molecular Medicine on the involvement of ALDH activity in r/r AML
Lyon (France), October 29, 2024 – Acute Myeloid Leukemia (AML) remains a major medical challenge despite recent advances in targeted molecular therapies. A recent study…
-
Advanced BioDesign announces exceptional first-in-human results for its innovative treatment against Acute Myeloid Leukemia
Drug candidate ABD-3001 is a galenic form of DIMATE, a first-in-class suicide inhibitor of aldehyde dehydrogenase 1 (ALDH1), being tested in relapsed patients with limited…
-
Advanced BioDesign joins forces with GTP Bioways to startmanufacturing of its innovative treatment for Acute MyeloidLeukemia (AML)
This partnership has been granted support from the Plan Innovation Santé 2030, a part ofthe France 2030 government program. ABD-3001 drug candidate is currently in…
